• Company
• Will the third time be the charm for Mylotarg?
• by Eo, Yun-Ho Oct 29, 2024 05:49am

• Company
• ABL Bio receives ₩7B as milestone payment from Sanofi
• by Kim, Jin-Gu Oct 29, 2024 05:49am

• Policy
• Low reimb approval rate hinders Soliris’s use for aHUS
• by Lee, Tak-Sun Oct 29, 2024 05:49am

• Policy
• COVID-19 treatments 'Paxlovid·Veklury' reimb begins today
• by Lee, Jeong-Hwan Oct 28, 2024 05:54am

• Company
• 'Aquipta,' new oral migraine drug, can be prescribed
• by Eo, Yun-Ho Oct 28, 2024 05:53am

• Company
• Will Roche’s lymphoma drug Columvi be discussed for reimb?
• by Eo, Yun-Ho Oct 28, 2024 05:53am

• Company
• "We have clinically proven Stelara for Koreans"
• by Moon, sung-ho Oct 28, 2024 05:53am

• Policy
• Switching between JAKis approved for atopic dermatitis
• by Lee, Tak-Sun Oct 28, 2024 05:53am

• Company
• Januvia generics occupy 17% of market in 1yr
• by Kim, Jin-Gu Oct 28, 2024 05:53am

• Policy
• Directly injected gene scissor therapy receives PT3 approval
• by Lee, Hye-Kyung Oct 25, 2024 05:49am